Phase 3 trials are expected to conclude in May 2026, with potential MHRA and FDA submissions anticipated in 2026 or 2027
This story mentions weight, weight loss, and/or prescription GLP-1 drugs, which are FDA-approved for weight management in adults diagnosed with obesity or with overweight and at least one weight-related health condition
After careful reflection, wrote a professor of medicine at the Mayo Clinic, most patients and clinicians may opt to avoid GLP-1 based drugs or at least avoid using them for a prolonged period of time. And this was all before this pivotal study came out, where researchers obtained transplant-quality pancreases from like accident victims who had been taking GLP-1 drugs for at least a year before they died, and every single pancreas showed abnormalities, marked enlargement, dysplasia, and even a few little tumors
This "priming" technique helps many people on early semaglutide treatment tolerate meals better
Within the skin, alpha-MSH participates in communication between keratinocytes, melanocytes and other cells
A new study found that females using GLP-1 drugs had about a 30% lower risk of developing breast cancer